

New CEO appointed at drug development company Biolipox

Stockholm

29 oktober, 2003

The Biolipox Board of Directors has appointed Torbjörn Bjerke as CEO, who will join the company during the month of December. Biolipox is a pharmaceutical R&D company with a world-class research profile within the field of inflammatory disease, particularly asthma and allergy.

Torbjörn Bjerke was previously Executive Vice President R&D at ALK-Abello, a world-leading company within allergy immunotherapy. Former start-up CEO, Carl-Johan Dalsgaard, will resume his position as Venture Partner, HealthCap.

"Biolipox has the basis for creating a world-leading drug development company within the field of inflammatory disease. From now on, focus will lie on partnering and out-licensing", Bjerke says. "Biolipox, with an impressive research portfolio, is among the most exciting and promising companies within its R&D area", Bjerke continues.

"Bjerke has a solid experience from the pharmaceutical industry, both from AstraZeneca and most recently from ALK-Abello, where he has developed his skills in managing an expanding business. Throughout his years in the pharmaceutical industry, he has gained the competence that will match the challenges that are ahead of Biolipox", says Eugen Steiner, President of the Board of Biolipox.

Biolipox was founded in 2000 by Professors Hans-Erik Claesson and Magnus Björkholm, both of the Karolinska Institute, after a seed financing by HealthCap. Based on a long tradition of world-leading research in the field of arachidonic acid, Biolipox's current pipeline comprises drugs targeting respiratory inflammatory diseases, particularly allergic rhinitis, and asthma, and inflammatory pain.

The achievements which form the foundation for the understanding of the role of arachidonic acid in inflammatory processes were rewarded with the 1982 Nobel Prize. Professor Bengt Samuelsson, one of the Nobel Prize winners, is a member of the Board at Biolipox.

Biolipox business concept involves producing innovative pharmaceuticals which meet medical needs in inflammatory disease, primarily asthma and pain. This is achieved in collaboration with researchers all over the world. At the point where the efficaciousness of the substances is proven, Biolipox will also be entering into license agreements with the major pharmaceuticals companies on the further development, marketing and sales of the product.

For more information:

Carl-Johan Dalsgaard, CEO; mobile: +46 70 975 98 63

Torbjörn Bjerke; +45 22 495 005

Biolipox AB is a pharmaceutical R&D company, focused on creating novel, efficacious and cost effective therapeutic opportunities for respiratory conditions and other inflammatory disorders. Biolipox' scientific platform is based on world-class arachidonic acid cascade research, performed at the Karolinska Institutet, and on development of nitric oxide (NO)-releasing drugs. The company has a broad portfolio of potential blockbusters in the respiratory therapy area and unique targets for novel anti-inflammatory and analgesic drugs.

Biolipox AB, Box 6280, SE-102 34 Stockholm, Sweden.

Tel: +46-8-545 28 140, Fax: +46-8-545 28 141, E-mail: carl-johan.dalsgaard@ofco.se

www.biolipox.com

